Current Trials and Research Opportunities Include:
Rockland Sample
This research program offers an opportunity for people of all ages—from 6 to 85—who live in Rockland County and neighboring areas to make a real difference.
Volunteer Recruitment Pool
The Volunteer Recruitment Pool (VRP) is the primary entry point for individuals (ages 6 and up) who are interested in research participation at the Nathan Kline Institute (NKI).
ADNI 4 (Alzheimer’s Disease Neuroimaging Initiative)
This study is sponsored by the NIH and will employ cutting-edge techniques to evaluate normal and pathological brain aging which could help change the future of Alzheimer’s disease. Poor memory is often viewed as a simple sign of getting older, complicating our understanding and treatment of Alzheimer’s disease. For more than a decade, ADNI researchers have worked tirelessly to better understand the disease and its progression in a way that will help the development of future treatment options, though no experimental medication will be involved in this study.
The Memory Education and Research Initiative (MERI Program)
The MERI program offers a comprehensive memory and cognitive evaluation at no cost, to individuals with memory complaints or a family history of Alzheimer’s disease (AD).
Transcranial photobiomodulation for mild cognitive impairment/Alzheimer’s Disease (TRAP-AD)
Are you experiencing memory problems? If you are 65+, you may qualify to participate in our study investigating an experimental treatment device for memory problems using near-infrared light therapy at the Nathan Kline Institute! Compensation will be provided for time and transportation.
A Randomized, Double-blind, Parallel Group, Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of ML-004 in Adolescents and Adults with Autism Spectrum Disorders (ASD)
The primary objective of this study is to evaluate the effectiveness and safety of ML-004-002, a new investigational medication, compared with placebo in improving social communication in autistic individuals.
Heterogeneity in OCD and Depression
This project aims to comprehensively characterize heterogeneity in Obsessive-Compulsive Disorder (OCD) and Major Depressive Disorder (MDD) in order to identify behavioral and neural markers that can be used as targets for future treatments.
Depression treatment and Aß dynamics: A study of Alzheimer’s disease risk (ABD Study)
The purpose of this research study is to test if a reduction in depressive symptoms in response to treatment with an antidepressant improves levels of certain proteins which have been associated with increased risk for the development of Alzheimer’s disease (AD).
Biobehavioral Predictors of Illness Progression in Adolescent Depression
Looking for paid research study participants. The participant and a parent will go through a free clinical evaluation with a clinician (remotely or in-person). The participant will have a blood draw and MRI scan. Your child will be compensated for the blood draw and scan and can win up to $60 in a game played in the scanner (totaling about $400).
Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression (TRIADE)
Do you have depression? Are you interested in experimental treatments for depression and contributing to depression research? If so, you may qualify to participate in our research study at NKI, IRB Study # i20-00217, that is investigating an experimental treatment device for depression using near-infrared light therapy.
Heterogeneity in OCD and Depression
This project aims to comprehensively characterize heterogeneity in Obsessive-Compulsive Disorder (OCD) and Major Depressive Disorder (MDD) in order to identify behavioral and neural markers that can be used as targets for future treatments.
Neural Mechanism of Active Avoidance in Obsessive-Compulsive Disorder
We are looking for individuals with Obsessive-Compulsive Disorder (OCD) for our study at the Nathan Kline Institute! The purpose of this study is to look at clinical symptoms, behavior, and brain function in the disorder.
Paid Research Study for OCD at The Nathan Kline Institute
We are looking for individuals with Obsessive-Compulsive Disorder (OCD) for our study at the Nathan Kline Institute! This study investigates the effects of transcranial magnetic stimulation (TMS) on brain function in patients with Obsessive-Compulsive Disorder (OCD).
A Multicenter, Randomized, Double-Blind, Parallel-Group, Controlled, 16-week Study to Evaluate the Efficacy and Safety of a Digital Therapeutic (CT-155) as an Adjunct to Standard-of-Care Antipsychotic Therapy in Adult and Late Adolescent Participants with Experiential Negative Symptoms of Schizophrenia (CLICK study)
CLICK/CONVOKE is a 22-week double blind digital therapeutic study that examines the efficacy of CT-155 as an adjunct treatment for patients diagnosed with experiential negative symptoms of schizophrenia. CT-155 is a novel PDT being developed by Click Therapeutics, Inc. (Click) and Boehringer Ingelheim (BI), collectively, the study “sponsor.” CT-155 delivers an interactive, software-based intervention for experiential negative symptoms of schizophrenia.
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia (Karuna Therapeutics)
The first non-antidopaminergic antipsychotic for outpatients. KarXT is a combined formulation of 2 study drugs, xanomeline tartrate and trospium chloride. Xanomeline, a cholinergic agonist, is combined with Trospium (FDA approved), which has been added to reduce the peripheral side effects of xanomeline tartrate, a central muscarinic agonist. KarXT is the first non-anti-dopaminergic antipsychotic to be developed.
The goal of this study is to see if KarXT combined with an antipsychotic drug works better than the current medicine alone. The study is also planned to see if both study drugs taken together are safe and well accepted by patients with schizophrenia.
Clozapine for the Prevention of Violence in Schizophrenia: A Randomized Clinical Trial
Two-hundred and eighty individuals with schizophrenia who have a recent history of violent acts will be randomized in this 2-arm, parallel-group, 24-week, open-label, 7-site clinical trial to examine the effects of treatment with clozapine vs. antipsychotic treatment as usual (TAU) for reducing the risk of violent acts in real-world settings.
Computerized facial and acoustic analysis during speech as a measurement of negative symptoms in schizophrenia
Dr. Anzalee Khan’s team is investigating an artificial intelligence (AI) enabled vocal and facial analysis, avatar driven software (called Neurological and Mental health Screening Instrument or NEMSI) to show good reliability and validity compared to existing clinician-administered psychiatric interview assessments, like: the Brief Negative Symptom Scale (BNSS), Positive and Negative Syndrome Scale (PANSS) Marder Negative Factor, and the Calgary Depression Scale (CDSS).
JOURNEY STUDY – “A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia” NBI-98854-ATS3019
The purpose of this Journey Study is to find out how safe the study drug, called valbenazine, is, how well the body handles taking it (tolerability), and how well it works as an add-on therapy in study participants with schizophrenia who did not respond well enough to antipsychotic therapy. This study aims to find out how well the study drug works compared to a placebo as an add-on therapy in participants who still experience symptoms. Placebos are made of a substance that looks just like the study drug being tested, but they contain no active ingredients. The first dose of study treatment will occur when subjects are enrolled (up to 4 weeks after the screening visit), and the follow-up period will be approximately 2 weeks following a participant’s final dose.
A pilot study examining integrated virtual reality avatar CBT for treatment refractory auditory hallucinations in individuals with schizophrenia
The aim of the study is to assess the efficacy of integrated virtual reality avatar CBT for improvements in persistent and treatment refractory auditory hallucinations in individuals with psychosis.
Schizophrenia Registry
The purpose of this project is to create a database, which will allow us to contact participants for active studies as well as other research opportunities within our program.
This database registry project is designed to give an opportunity to interested patients with schizophrenia or schizoaffective disorder to have access to the various research studies that the MPC Research Program has available.